Document is current
Any future updates will be listed below
-
Authors
Sassani, Matilde https://orcid.org/0000-0002-0384-7296
Mitchell, James L.
Yiangou, Andreas https://orcid.org/0000-0001-8905-5734
Davies, Nigel
Sawlani, Vijay
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Wagshul, Mark E.
Sinclair, Alexandra J. https://orcid.org/0000-0003-2777-5132
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (NIHR-CS-011-028)
Ministry of Defence
Association of British Neurologists and Guarantors of the Brain fellowship
RCUK | Medical Research Council (MR/K015184/1)
- License Information
-
More Information
Article History
Received: 12 June 2023
Revised: 28 November 2024
Accepted: 11 December 2024
First Online: 24 January 2025
Competing interests
: JLM was funded by the UK Ministry of Defence for the duration of the study. AY is funded by an Association of British Neurologists and Guarantors of the Brain fellowship. AY reports receiving speaker fees from Teva, UK, outside the submitted work. Professor Mollan reports consultancy fees (Invex Therapeutics; Velux foundation); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera). Professor Sinclair reports personal fees from Invex therapeutics in her role as Director with stock holdings, during the conduct of the study (since 28.06.2019); other for advisory boards from Allergan, Novartis, Cheisi and Amgen outside the submitted work. All other authors declare no competing interests.
